Background: Programmed cell death 1 (PD-1) inhibitors act as immune checkpoint inhibitors and are more effective for improving survival time with less toxicity as compared with conventional chemotherapies. In anti PD-1 therapy, it is important to evaluate metabolism in the cancer microenvironment, as this helps to clarify the pathological conditions. Herein, we investigate the early effects of PD-1 therapy on 2-deoxy-2-[
Background
The interaction between programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) is a mechanism involved in the ability of immunogenic tumors to escape the immune response. Blockade of this interaction activates autoimmunity towards the tumor and provides a strategy for tumor immunotherapy [1] . Many classes of immune checkpoint inhibitors have been or are being developed, such as the PD-1 inhibitors (e.g., nivolumab) [2] . The results of clinical studies have shown that PD-1 inhibitors are more effective in improving survival time and less toxic than conventional chemotherapies [3] , which has sparked worldwide interest in their therapeutic potential.
Immune checkpoint inhibitors target immune systems; thus, interaction between immune and tumor cells is important for therapeutic effects. Unlike in the case of chemotherapies which directly target cancer cells, immunotherapeutic effects appear late and sometimes after an initial increase in tumor burden or the appearance of new lesions [4] . Therefore, therapeutic effects in the early stages of treatment need to be determined not by tumor volume. Thus, molecular imaging technique (e.g., positron emission tomography; PET) should be helpful for evaluating the therapeutic effect.
Along with the development of immune checkpoint inhibitors, metabolism in the cancer microenvironment has received a great deal of attention because it is important for understanding how tumor and immune cells share or compete for resources and how such relationships regulate antitumor immunity [4, 5] . For example, it has been proposed that T cell activation requires metabolic reprogramming including that of glycolysis [6] . However, recent studies have demonstrated that the glycolytic activity of cancer cells may restrict glucose utilization by tumor-infiltration lymphocytes (TILs), thereby impairing antitumor immunity, and that checkpoint blockade antibodies restore glucose in the tumor microenvironment, permitting T cell glycolysis and interferon-gamma (IFN-γ) production [7, 8] [9, 10] ; however, others have shown the opposite effect [9, 11, 12] . Anti PD-1 and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are used as checkpoint inhibitors in clinic. These are different molecule-targeted immuno-therapeutics, and the response pattern might be different. In fact, there is not much known about the early response pattern of PD-1-therapy in [ These unidentified points about [
18 F]FDG uptake in anti PD-1 therapy may be described by focusing on cancer cells, which are also known as high-glycolysis cells [13] . However, few studies to date have focused on cancer cell metabolism in immune checkpoint therapy. It is important to evaluate metabolism not only in infiltrated immune cells but also of cancer cells in the cancer microenvironment, as doing so can contribute to clarifying pathological conditions and also has applications for imaging. Herein, we report on the early effect of PD-1 therapy on [ 
Methods

Cell line
The B16F10 melanoma cell line was purchased from ATCC (Manassas, VA, USA) in 2016. Cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 2 mmol/L L-glutamine.
Mouse models
Animal care, experiments, and euthanasia were performed in accordance with protocols approved by the Hokkaido University Animal Research Committee. Male C57BL/6JJmsSlc mice (7-10 weeks old) were purchased from Sankyo Labo Service Corporation, Inc. (Tokyo, Japan). Animal experiments were performed in specific pathogen-free facilities. Mice were inoculated subcutaneously with 5 × 10 5 B16F10 cells in 100 μL of phosphate-buffered saline (PBS). Anti PD-1 treatment was started when tumor presence was confirmed. Anti-mouse PD-1 (clone RMP1-14) was purchased from BioXcell (West Lebanon, NH, USA). Anti PD-1 antibody (250 μg in 200 μL PBS) was administrated twice i.p. 5 days apart. Tumor measurements were made two to three times weekly using calipers, and the volume was expressed in mm 3 
(L, long diameters; W, short diameters of the tumor). [ 18 F]FDG-PET/Computed Tomography (CT) imaging was performed just prior to initiating therapy and at 7 days after the initiation of anti PD-1 treatment initiation (Fig. 1a) . The end-point was when tumor size reached 10% of the body weight.
In this study, treatment group was defined as the group which was treated by anti PD-1 antibody twice a week and non-treatment group was defined as the group which was not treated by anti PD-1 antibody. Fifty-seven mice were used in total (treatment group n = 27, non-treatment group n = 25, pre-treatment group n = 5); among these mice, 10 mice for PET (treatment group n = 5, non-treatment group n = 5), 40 mice for flow-cytometry (treatment group n = 18, non-treatment group n = 17, pre-treatment group n = 5, 2-4 markers were analyzed in each mouse, and n = 5-6 for each marker), and 4 mice for histopathology and autoradiography (treatment group n = 2, non-treatment group n = 2). [14] . During imaging, anesthesia was maintained with 1% isoflurane. CT scanning was performed from 20 min after the tracer injection, and PET scanning was performed for 10 min beginning 40 min after the tracer injection.
PET imaging
Acquired PET-CT images were reconstructed using the filtered back projection (FBP) algorithm with the ramp filter cut-off at the Nyquist frequency. The image matrix was 256 × 256 × 318, resulting in a voxel size of 0.388 × 0.388 × 0.398 mm 3 . CT was performed for attenuation correction. The half rotation step-and-shoot mode was used for CT data acquisition. The radiographic source was operated at 500 μA and 80 kVp. Images were reconstructed using a Feldkamp cone-beam algorithm, with a Shepp-Logan filter.
PET-CT images and three-dimensional regions of interest (volume of interest; VOI) of tumors were computed using Inveon Research Workplace software (Siemens Medical Solutions). All radioactivity concentration values were normalized according to the percentage-injected activity per gram of tissue (%IA/g), and the maximum or mean %IA/g value obtained in VOI was considered for quantitative analysis.
After PET imaging on day 7, the mice were sacrificed and their organs were dissected. Tissues (tumor xenografts, spleens, and blood) were weighed, and radioactivity was measured using a gamma counter (2480 Wizard 2 gamma counter, PerkinElmer, Waltham, MA, USA). Data were calculated as %IA/g.
Flow-cytometry analysis
Tumors were harvested and processed using Collagenase I and DNase I (Wako, Osaka, Japan). The resulting cell suspensions were clarified using 40-μm filters to prepare single cell suspensions, and single cells were suspended in PBS supplemented with 2% FBS. Splenocytes were hemolyzed and incubated with anti-CD16/32 2.4G2 (BD Biosciences, San Jose, CA, USA) to reduce FcγR binding. Cell-surface antigens were stained with antibodies specific for CD8 (BioLegend, San Diego, CA, USA, clone 53-6.7), CD4 (BioLegend, clone GK1. For intracellular staining, cells were fixed and permeabilized using Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA) after cell surface staining and were stained with labeled antibodies against the intracellular molecules foxp3 (eBioscience, clone FJK-16s), glucose transporter 1 (GLUT1, Abcam, Cambridge, UK, clone EPR3915), and hexokinase II (HX2, Abcam, clone EPR20839).
Samples were analyzed on a FACS Calibur HG flow cytometer (BD Biosciences). Data analysis was performed with CellQuest™ software (Becton Dickinson, Lincoln Park, NJ, USA).
Histopathology and autoradiography
C57/BL6 mice (n = 2) were fasted for 12 h, and then [ F]FDG injection, and tumor tissues were embedded in optimal cutting temperature (OCT) compound and immediately snap-frozen. Serial 5-μm tumor sections were placed onto glass slides, dried, and fixed at room temperature. Slices were used for autoradiography and hematoxylin-eosin (HE) staining. Autoradiograms were obtained using a 
Statistics
Statistical analyses were performed using JMP pro 3.0 software (SAS Institute Inc., Cary, NC, USA). Results are expressed as mean ± SEM. Statistical significance was determined by two-tailed Student's or Welch's t test, and a P value less than 0.05 was considered statistically significant.
Results
In vivo [ ]FDG in the treatment group tumors tended to be higher (19.14 ± 1.86 %IA/g; P = 0.0839) than that in the non-treatment group (14.24 ± 1.64 %IA/g).
Ex vivo validation
As was the case with PET-CT, the uptake of [
18 F]FDG in treatment group tumors was significantly different from that of the non-treatment group (P = 0.0126), but the uptake of [
18 F]FDG in the spleen and blood did not differ from that of the non-treatment group (Fig. 2a) .
The regional distribution of [ 18 F]FDG was assessed by autoradiography, and the autoradiographs were compared with HE-stained samples (Fig. 2b) . The results confirmed the uptake of [
18 F]FDG in non-necrotic areas, and the pathological images showed no significant difference between the treatment group and the non-treatment group. + and CD4 + T cells, although the difference was not significant except for %CD4 + of CD45 + cells (Fig. 3a) . There was no effect on Treg infiltration. But since the infiltration levels of these cells were small, the results should not largely affect [ 18 F]FDG uptake. Among CD45 + tumor cells, anti PD-1 treatment significantly increased the frequency of effector CD4 + T cells (Fig. 3a) . In addition, among all tumor cells, anti PD-1 treatment did not lead to increased frequencies of F4/80 + CD11b + macrophages (MΦ) and IA/IE + CD11c + dendritic cells (DC) (Fig. 3b) . Infiltration of these immune cells (T cells, MΦ and DC) into tumor tissues was negligible at around 1%.
In contrast, anti PD-1 treatment significantly enriched CD4 + T cells among CD45 + splenic cells and significantly reduced CD8
+ T cells among all splenic cells (Fig. 3c) . However, the change in the number of splenic T cells was only around 2% and it should not affect the [ 18 F]FDG uptake in the spleen. Additionally, anti PD-1 treatment did not affect the ratio of MΦ and DC to all splenic cells (Fig. 3d) .
Tumor and splenic metabolism of glucose
We measured the expression of GLUT1 and hexokinase II in tumors to better understand glucose metabolism in cancer and immune cells. Table S1 ). However, the Thus, in this study, experiments were conducted using a B16F10 melanoma model, which is popular for PD-1 blockade studies, focusing on changes in immune cell distribution and the functional glucose metabolic rate. Significant inhibition of tumor growth was not detected by anti PD-1 treatment during our observation period (7 days), but it is reported that tumor growth would be inhibited 12 days after anti PD-1 treatment in the same animal model [16] . However, [ 18 F]FDG uptake in the treatment group tumors was higher than that in the non-treatment group tumors following treatment, as shown by PET-CT and ex vivo validation, on day 7. Since the tumor growth was very fast in this animal model and necrotic lesion in the tumor was detected on day 7, decrease in [
18 F]FDG uptake was observed in non-treatment group. Other studies have reported the use of [
18 F]FDG-PET/CT scanning for predicting the early response to immune checkpoint inhibitors clinically [9] [10] [11] [12] . One such study reported that [ 18 F]FDG uptake in treatment-responsive patients increased in the early stage of immune checkpoint inhibition therapy for melanoma [10] which agrees with our results. This clinical study also suggests that increased [ 18 F]FDG uptake may correlate with eventual clinical benefit. Our observation period in this mouse model should be too early to see the therapeutic response, since the model is poorly immunogenic. But, there is a report that significant therapy response could be observed even after the first cycle of anti PD-1 therapy [17] . This would also explain why there was no increased [ 18 F]FDG-uptake in the spleen observed, although it is reported in other studies [18, 19] .
As for increased [ 18 F]FDG uptake in treatment group tumors, we assumed that infiltration of inflammatory immune cells caused [ 18 F]FDG uptake to be increased. To clarify which immune cells contribute to increase [ 18 F]FDG uptake and determine how they affect [ 18 F]FDG uptake, flow-cytometry analysis was performed. The results of the assessment of tumor immune cell populations in tumors showed that anti PD-1 treatment slightly enriched CD8 + and CD4 + T cells, but it did not affect the infiltration of Tregs, MΦ, and DC. Not all kinds of immune cells were investigated in our study, and such investigation should be useful to further understand the observation in the future. Moreover, infiltration of these immune cells into tumor tissues was negligible so this result cannot explain the increase in [ 18 F]FDG uptake. In fact, the B16 melanoma model is poorly immunogenic compared to the CT26 colon model [20] . In clinical studies, patients who respond to PD-1 blockade often show high numbers of CD8-expressing cells in tumors [21] . Therefore, in a strongly immunogenic mouse model, infiltration of inflammatory immune cells may cause [ 18 F]FDG uptake to be increased. In our B16F10 tumor model, we performed flow-cytometry analysis focusing on GLUT1 and hexokinase II to clarify the mechanism of increased [ 18 [22] . Also, there is a report that expression of PD-L1 is associated with the expression of GLUT1 [7, 23] , and Haratake et al. have reported positive conversion of PD-L1 expression on cancer cells after anti PD-1 treatment [24] .
Additional work is needed to identify the mechanisms by which glycolysis is increased in cancer cells, which may ultimately help to make PD-1 therapy more effective. Notably 
Conclusion
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